Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine
S Takashima, Y Oka, F Fujiki, S Morimoto, H Nakajima… - 2016 - Future Science
... against WT1-expressing tumor cells. GMP-grade WT1 peptide was purchased from
Multiple Peptide Systems (CA, USA) and Peptide Institute (Osaka, Japan) as the
lyophilized peptide. Patients Sixty patients were enrolled in ...
Multiple Peptide Systems (CA, USA) and Peptide Institute (Osaka, Japan) as the
lyophilized peptide. Patients Sixty patients were enrolled in ...
Eva He
eva@pepmic.com
Pepmic Co., Ltd
www.pepmic.com
没有评论:
发表评论